British journal of cancer · 1994

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Riccardi A, Ucci G, Luoni R, Brugnatelli S, Mora O, Spanedda R, De Paoli A, Barbarano L, Di Stasi M, Alberio F

Аннотация

The purpose of the study was to ascertain whether the prognostic significance of staging in multiple myeloma (MM) is influenced by the aggressiveness of effective induction treatment and/or by continuing or discontinuing maintenance chemotherapy. Patients with untreated stage I MM (defined according to Durie and Salmon) were randomised between being followed without cytostatics until the disease progressed and receiving six courses of melphalan and prednisone (MP-P) just after diagnosis; stage II patients were uniformly treated with MPH-P and stage III patients were randomised between MPH-P and four courses of combination chemotherapy with Peptichemio, vincristine and prednisone (PTC-VCR-P). Within each stage, responsive patients were randomised between receiving additional therapy only until maximal tumour reduction was reached (plateau phase) and continuing induction therapy indefinitely until relapse. With resistant, progressive or relapsing disease, patients originally treated with MPH-P for induction received combination chemotherapy and vice versa. The overall first response rate was 43.8% (42.2% in 206 stage I, II and III patients treated with MPH-P and 48.0% in 75 stage III patients treated with combination chemotherapy, P = NS). Combination chemotherapy was more myelotoxic than MPH-P and, in particular, caused more non-haematological side-effects. Both the less and the more aggressive induction policies gave the same disease control. Progression of disease was statistically similar in stage I patients who were initially left untreated and in t hose who received MPH-P just after diagnosis; median duration of first response was similar in stage III patients receiving MPH-P and in those on combination chemotherapy. In all stages, discontinuing or continuing maintenance did not alter the median duration of first response. The overall second response rate was 28.5% (34.0% to MPH-P and 25.3% to combination chemotherapy, P = NS). Median survival was greater than 78 months in stage I, was 46.3 months in stage II and was 24.3 months in stage III patients, still independent of both induction and post-induction policies. In MM, the significance of staging for survival is independent of both the aggressiveness of induction and of continuing or discontinuing maintenance chemotherapy after the maximal tumor reduction has been achieved. Both MPH-P and and the association of PTC, VCR and P are effective in inducing first response and also second response in patients failing on the alternative regimen, but PTC-VCR-P causes more side effects. Thus, the overwhelming majority of patients with MM can safely be given MPH-P as first therapy, and this treatment may be delayed in early diseases.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Abramson N. Lurie P. Mietlowski W. L. Schilling A. Bennett J. M. Horton J. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. 66 6 6 1982 1273 1277 Cancer Treat Rep 7044535

Alexanian R. Gehan E. Haut A. Saiki J. Weick J. Unmaintained remissions in multiple myeloma. 51 6 6 1978 1005 1011 Blood 647110

Belch A. Shelley W. Bergsagel D. Wilson K. Klimo P. White D. Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. 57 1 1 1988 94 99 Br J Cancer PMC2246700 3279997 10.1038/bjc.1988.17

Bergsagel D. E. Bailey A. J. Langley G. R. MacDonald R. N. White D. F. Miller A. B. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. 301 14 4 10 1979 743 748 N Engl J Med 481481 10.1056/NEJM197910043011402

Boccadoro M. Marmont F. Tribalto M. Avvisati G. Andriani A. Barbui T. Cantonetti M. Carotenuto M. Comotti B. Dammacco F. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. 9 3 3 1991 444 448 J Clin Oncol 1999714 10.1200/JCO.1991.9.3.444

Boros L. Chuang C. Butler F. O. Bennett J. M. Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation. 56 9 1 11 1985 2161 2169 Cancer 3902204 10.1002/1097-0142(19851101)56:9<2161::aid-cncr2820560904>3.0.co;2-m

Buzaid A. C. Durie B. G. Management of refractory myeloma: a review. 6 5 5 1988 889 905 J Clin Oncol 2452861 10.1200/JCO.1988.6.5.889

Cavagnaro F. Lein J. M. Pavlovsky S. Becherini J. O. Pileggi J. E. Micheo E. Q. Jait C. Musso A. Suárez A. Pizzolato M. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. 64 1 1 1980 73 79 Cancer Treat Rep 6991106

Cavo M. Gobbi M. Tura S. Peptichemio in multiple myeloma. (Preliminary results). 66 2 4 1981 208 215 Haematologica 6791997

Cohen H. J. Silberman H. R. Larsen W. E. Johnson L. Bartolucci A. A. Durant J. R. Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. 54 4 10 1979 824 836 Blood 476303

Cooper M. R. McIntyre O. R. Propert K. J. Kochwa S. Anderson K. Coleman M. Kyle R. A. Prager D. Rafla S. Zimmer B. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. 4 9 9 1986 1331 1339 J Clin Oncol 3528403 10.1200/JCO.1986.4.9.1331

Durie B. G. Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. 36 3 9 1975 842 854 Cancer 1182674 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u

Gahrton G. Tura S. Ljungman P. Belanger C. Brandt L. Cavo M. Facon T. Granena A. Gore M. Gratwohl A. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. 325 18 31 10 1991 1267 1273 N Engl J Med 1922221 10.1056/NEJM199110313251802

Gregory W. M. Richards M. A. Malpas J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. 10 2 2 1992 334 342 J Clin Oncol 1531068 10.1200/JCO.1992.10.2.334

Harley J. B. Pajak T. F. McIntyre O. R. Kochwa S. Cooper M. R. Coleman M. Cuttner J. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. 54 1 7 1979 13 22 Blood 444661

Hjorth M. Hellquist L. Holmberg E. Magnusson B. Rödjer S. Westin J. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. 74 2 2 1990 185 191 Br J Haematol 2180471 10.1111/j.1365-2141.1990.tb02564.x

Hjorth M. Hellquist L. Holmberg E. Magnusson B. Rödjer S. Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. 50 2 2 1993 95 102 Eur J Haematol 8440364 10.1111/j.1600-0609.1993.tb00148.x

Kildahl-Andersen O. Bjark P. Bondevik A. Bull O. Burgess G. Dehli O. Hoel S. Jaeger S. Kvambe V. Mürer F. Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy. 41 1 7 1988 47 51 Eur J Haematol 3042453 10.1111/j.1600-0609.1988.tb00867.x

MacLennan I. C. Chapman C. Dunn J. Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. 339 8787 25 1 1992 200 205 Lancet 1346171 10.1016/0140-6736(92)90004-m

MacLennan I. C. Cusick J. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. 52 2 8 1985 153 158 Br J Cancer PMC1977102 3896288 10.1038/bjc.1985.171

MacLennan I. C. Kelly K. Crockson R. A. Cooper E. H. Cuzick J. Chapman C. Results of the MRC myelomatosis trials for patients entered since 1980. 6 2 Apr-Jun 1988 145 158 Hematol Oncol 3292372 10.1002/hon.2900060215

Merlini G. Gobbi P. G. Riccardi A. Riva G. Sardi C. Perugini S. Peptichemio induction therapy in myelomatosis. 8 1 1982 9 16 Cancer Chemother Pharmacol 7094202 10.1007/BF00292864

Merlini G. Riccardi A. Riccardi P. G. Montecucco C. M. Pavesi F. Ascari E. Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. 71 6 31 12 1985 581 588 Tumori 4082291 10.1177/030089168507100611

Monconduit M. Menard J. F. Michaux J. L. Le Loet X. Bernard J. F. Grosbois B. Pollet J. P. Azais I. Laporte J. P. Doyen C. VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM). 80 2 2 1992 199 204 Br J Haematol 1550777 10.1111/j.1365-2141.1992.tb08901.x

Montecucco C. Riccardi A. Merlini G. Ascari E. Complete remission in plasma cell leukaemia. 62 3 3 1986 525 527 Br J Haematol 3954966 10.1111/j.1365-2141.1986.tb02964.x

Montecucco C. Riccardi A. Merlini G. Mazzini G. Giordano P. Danova M. Ascari E. Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. 20 1 1 1984 81 90 Eur J Cancer Clin Oncol 6537918 10.1016/0277-5379(84)90038-5

Peest D. Deicher H. Coldewey R. Schmoll H. J. Schedel I. Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. 24 6 6 1988 1061 1067 Eur J Cancer Clin Oncol 3044800 10.1016/0277-5379(88)90160-5

Riccardi A. Giordano M. Girino M. Treatment of adult acute non-lymphoblastic leukemia: a computer-aided analysis. 72 1 Jan-Feb 1987 71 88 Haematologica 3108100

Riccardi A. Gobbi P. G. Ucci G. Bertoloni D. Luoni R. Rutigliano L. Ascari E. Changing clinical presentation of multiple myeloma. 27 11 1991 1401 1405 Eur J Cancer 1835856 10.1016/0277-5379(91)90020-e

Riccardi A. Martinotti A. Perugini S. Cytokinetic changes in two cases of plasma leukemia treated with a multipeptide derivative of m-[di(2-chloroethyl)amino]-L-phenylalanine (Peptichemio). 14 10 10 1978 1099 1106 Eur J Cancer 710479 10.1016/0014-2964(78)90065-8

Riccardi A. Merlini G. Montecucco C. Danova M. Ucci G. Cassano E. Ascari E. Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. 22 7 7 1986 787 791 Eur J Cancer Clin Oncol 3770037 10.1016/0277-5379(86)90364-0

Riccardi A. Montecucco C. Danova M. Ucci G. Merlini G. Ascari E. Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. 69 9 9 1985 971 975 Cancer Treat Rep 4028038

Riccardi A. Montecucco C. Merlini G. Ucci G. Cremonini N. Gobbi P. G. Ascari E. Proliferative activity, response to therapy and survival in multiple myeloma. 69 2 Mar-Apr 1984 148 162 Haematologica 6429002

Riccardi A. Ucci G. Luoni R. Castello A. Coci A. Magrini U. Ascari E. Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma. 43 6 6 1990 469 475 J Clin Pathol PMC502499 2199532 10.1136/jcp.43.6.469

Salmon S. E. Haut A. Bonnet J. D. Amare M. Weick J. K. Durie B. G. Dixon D. O. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. 1 8 8 1983 453 461 J Clin Oncol 6366141 10.1200/JCO.1983.1.8.453

Ucci G. Petrini M. Riccardi A. Invernizzi R. Carulli G. Luoni R. Giordano M. Danova M. Expression of p170 protein in multiple myeloma: a clinical study. 10 3-4 May-Aug 1992 213 220 Hematol Oncol 1356905 10.1002/hon.2900100312

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Ошибки и ограничения

Аннотация